Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1 Study With Expansion Cohorts to Assess the Safety, Tolerability, and Activity of Oraxol (Paclitaxel + HM30181A) in Combination With Pembrolizumab in Subjects With Advanced Solid Malignancies

Next Previous
Trial Profile

Phase 1 Study With Expansion Cohorts to Assess the Safety, Tolerability, and Activity of Oraxol (Paclitaxel + HM30181A) in Combination With Pembrolizumab in Subjects With Advanced Solid Malignancies

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 17 Jan 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs HM 30181A (Primary) ; Paclitaxel (Primary) ; Pembrolizumab (Primary)
  • Indications Adenocarcinoma; Gastric cancer; Non-small cell lung cancer; Oesophageal cancer; Solid tumours; Urogenital cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Athenex

    • Most Recent Events

    • 08 Jan 2019 Planned primary completion date changed from 30 Jul 2020 to 30 Oct 2020.
    • 08 Jan 2019 Status changed from not yet recruiting to recruiting.
    • 26 Nov 2018 According to Athenex media release, company initiates this study.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top